SLC5A2 and chronic kidney disease: However, the incidence of all-cause mortality was similar in the SGLT-2 inhibitor and placebo arms in patients without CKD: RR 0.84 (95% CI 0.69–1.01; P = 0.06) (Supplemental Fig. 5 and Table 3).